CRVS Corvus Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRVS

Price (delayed)

$1.92

Market cap

$94.15M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.56

Enterprise value

$82.91M

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells ...

Highlights
The debt has contracted by 47% YoY and by 19% from the previous quarter
The EPS has increased by 37% YoY and by 13% QoQ
Corvus Pharmaceuticals's equity has decreased by 31% YoY and by 13% QoQ
The quick ratio has contracted by 10% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.corvuspharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of CRVS
Market
Shares outstanding
49.04M
Market cap
$94.15M
Enterprise value
$82.91M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.43
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$27.03M
EBITDA
-$26.88M
Free cash flow
-$23.97M
Per share
EPS
-$0.56
Free cash flow per share
-$0.5
Book value per share
$0.79
Revenue per share
$0
TBVPS
$0.95
Balance sheet
Total assets
$45.55M
Total liabilities
$6.87M
Debt
$1.37M
Equity
$38.68M
Working capital
$21.09M
Liquidity
Debt to equity
0.04
Current ratio
4.07
Quick ratio
3.96
Net debt/EBITDA
0.42
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-50.6%
Return on equity
-59.6%
Return on invested capital
-76.8%
Return on capital employed
-69.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRVS stock price

How has the Corvus Pharmaceuticals stock price performed over time
Intraday
10.98%
1 week
32.41%
1 month
9.71%
1 year
69.91%
YTD
9.09%
QTD
7.87%

Financial performance

How have Corvus Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.41M
Net income
-$27.03M
Gross margin
N/A
Net margin
N/A
Corvus Pharmaceuticals's net income has increased by 35% YoY and by 10% QoQ
The operating income rose by 28% year-on-year

Growth

What is Corvus Pharmaceuticals's growth rate over time

Valuation

What is Corvus Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.43
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 37% YoY and by 13% QoQ
The price to book (P/B) is 74% higher than the 5-year quarterly average of 1.4 and 43% higher than the last 4 quarters average of 1.7
Corvus Pharmaceuticals's equity has decreased by 31% YoY and by 13% QoQ

Efficiency

How efficient is Corvus Pharmaceuticals business performance
The ROE is down by 4.9% year-on-year
The company's return on assets fell by 4.8% YoY

Dividends

What is CRVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRVS.

Financial health

How did Corvus Pharmaceuticals financials performed over time
Corvus Pharmaceuticals's total liabilities has decreased by 43% YoY and by 10% QoQ
The total assets has contracted by 33% YoY and by 12% from the previous quarter
The debt is 96% less than the equity
The debt has contracted by 47% YoY and by 19% from the previous quarter
Corvus Pharmaceuticals's equity has decreased by 31% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.